Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.40
QGEN's Cash to Debt is ranked lower than
75% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. QGEN: 0.40 )
Ranked among companies with meaningful Cash to Debt only.
QGEN' s Cash to Debt Range Over the Past 10 Years
Min: 0.31  Med: 0.95 Max: N/A
Current: 0.4
Equity to Asset 0.61
QGEN's Equity to Asset is ranked higher than
50% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. QGEN: 0.61 )
Ranked among companies with meaningful Equity to Asset only.
QGEN' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.61 Max: 0.72
Current: 0.61
0.44
0.72
Interest Coverage 4.70
QGEN's Interest Coverage is ranked lower than
83% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. QGEN: 4.70 )
Ranked among companies with meaningful Interest Coverage only.
QGEN' s Interest Coverage Range Over the Past 10 Years
Min: 2.05  Med: 5.09 Max: 15.97
Current: 4.7
2.05
15.97
F-Score: 5
Z-Score: 2.75
M-Score: -2.64
WACC vs ROIC
6.68%
5.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.71
QGEN's Operating margin (%) is ranked higher than
85% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. QGEN: 13.71 )
Ranked among companies with meaningful Operating margin (%) only.
QGEN' s Operating margin (%) Range Over the Past 10 Years
Min: 4.86  Med: 14.93 Max: 23.8
Current: 13.71
4.86
23.8
Net-margin (%) 9.93
QGEN's Net-margin (%) is ranked higher than
81% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. QGEN: 9.93 )
Ranked among companies with meaningful Net-margin (%) only.
QGEN' s Net-margin (%) Range Over the Past 10 Years
Min: 5.31  Med: 10.15 Max: 15.62
Current: 9.93
5.31
15.62
ROE (%) 5.11
QGEN's ROE (%) is ranked higher than
59% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. QGEN: 5.11 )
Ranked among companies with meaningful ROE (%) only.
QGEN' s ROE (%) Range Over the Past 10 Years
Min: 2.49  Med: 5.66 Max: 15.46
Current: 5.11
2.49
15.46
ROA (%) 3.08
QGEN's ROA (%) is ranked higher than
63% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. QGEN: 3.08 )
Ranked among companies with meaningful ROA (%) only.
QGEN' s ROA (%) Range Over the Past 10 Years
Min: 1.65  Med: 3.29 Max: 8.9
Current: 3.08
1.65
8.9
ROC (Joel Greenblatt) (%) 24.70
QGEN's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. QGEN: 24.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.11  Med: 33.19 Max: 45.64
Current: 24.7
10.11
45.64
Revenue Growth (3Y)(%) 6.70
QGEN's Revenue Growth (3Y)(%) is ranked higher than
53% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. QGEN: 6.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
QGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.2  Med: 8.50 Max: 44.5
Current: 6.7
-2.2
44.5
EBITDA Growth (3Y)(%) 9.30
QGEN's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. QGEN: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.1  Med: 11.05 Max: 48.8
Current: 9.3
-9.1
48.8
EPS Growth (3Y)(%) 8.60
QGEN's EPS Growth (3Y)(%) is ranked higher than
60% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. QGEN: 8.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
QGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.9  Med: 11.10 Max: 46.8
Current: 8.6
-22.9
46.8
» QGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

QGEN Guru Trades in Q1 2015

Paul Tudor Jones 9,500 sh (New)
Jim Simons 33,656 sh (New)
PRIMECAP Management 22,731,216 sh (+2.01%)
Manning & Napier Advisors, Inc 2,162,732 sh (-2.77%)
» More
Q2 2015

QGEN Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 2,471,378 sh (+14.27%)
Paul Tudor Jones 9,500 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 22,703,966 sh (-0.12%)
» More
Q3 2015

QGEN Guru Trades in Q3 2015

Manning & Napier Advisors, Inc 2,720,153 sh (+10.07%)
Paul Tudor Jones Sold Out
PRIMECAP Management 21,856,896 sh (-3.73%)
» More
Q4 2015

QGEN Guru Trades in Q4 2015

Jim Simons 210,223 sh (New)
PRIMECAP Management 20,532,325 sh (-6.06%)
» More
» Details

Insider Trades

Latest Guru Trades with QGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 50.11
QGEN's P/E(ttm) is ranked lower than
75% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.35 vs. QGEN: 50.11 )
Ranked among companies with meaningful P/E(ttm) only.
QGEN' s P/E(ttm) Range Over the Past 10 Years
Min: 23.25  Med: 39.55 Max: 148.96
Current: 50.11
23.25
148.96
Forward P/E 17.36
QGEN's Forward P/E is ranked higher than
60% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.92 vs. QGEN: 17.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 48.79
QGEN's PE(NRI) is ranked lower than
73% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. QGEN: 48.79 )
Ranked among companies with meaningful PE(NRI) only.
QGEN' s PE(NRI) Range Over the Past 10 Years
Min: 23.25  Med: 39.52 Max: 147.94
Current: 48.79
23.25
147.94
P/B 1.91
QGEN's P/B is ranked higher than
64% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. QGEN: 1.91 )
Ranked among companies with meaningful P/B only.
QGEN' s P/B Range Over the Past 10 Years
Min: 1.19  Med: 1.86 Max: 2.63
Current: 1.91
1.19
2.63
P/S 3.80
QGEN's P/S is ranked lower than
68% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. QGEN: 3.80 )
Ranked among companies with meaningful P/S only.
QGEN' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 4.07 Max: 5.49
Current: 3.8
2.8
5.49
PFCF 21.40
QGEN's PFCF is ranked higher than
72% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.05 vs. QGEN: 21.40 )
Ranked among companies with meaningful PFCF only.
QGEN' s PFCF Range Over the Past 10 Years
Min: 19.02  Med: 34.29 Max: 53.67
Current: 21.4
19.02
53.67
POCF 13.64
QGEN's POCF is ranked higher than
77% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.46 vs. QGEN: 13.64 )
Ranked among companies with meaningful POCF only.
QGEN' s POCF Range Over the Past 10 Years
Min: 11.72  Med: 18.90 Max: 31.91
Current: 13.64
11.72
31.91
EV-to-EBIT 39.77
QGEN's EV-to-EBIT is ranked lower than
80% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.84 vs. QGEN: 39.77 )
Ranked among companies with meaningful EV-to-EBIT only.
QGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: 16.6  Med: 37.25 Max: 92.9
Current: 39.77
16.6
92.9
EV-to-EBITDA 21.70
QGEN's EV-to-EBITDA is ranked lower than
76% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.36 vs. QGEN: 21.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
QGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 16.40 Max: 29.2
Current: 21.7
9.4
29.2
PEG 242.00
QGEN's PEG is ranked lower than
100% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. QGEN: 242.00 )
Ranked among companies with meaningful PEG only.
QGEN' s PEG Range Over the Past 10 Years
Min: 2.21  Med: 3.94 Max: 617.3
Current: 242
2.21
617.3
Shiller P/E 48.89
QGEN's Shiller P/E is ranked lower than
72% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. QGEN: 48.89 )
Ranked among companies with meaningful Shiller P/E only.
QGEN' s Shiller P/E Range Over the Past 10 Years
Min: 26.17  Med: 43.38 Max: 67.18
Current: 48.89
26.17
67.18
Current Ratio 3.52
QGEN's Current Ratio is ranked higher than
59% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. QGEN: 3.52 )
Ranked among companies with meaningful Current Ratio only.
QGEN' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 3.09 Max: 6.29
Current: 3.52
1.45
6.29
Quick Ratio 3.04
QGEN's Quick Ratio is ranked higher than
61% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. QGEN: 3.04 )
Ranked among companies with meaningful Quick Ratio only.
QGEN' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 2.56 Max: 5.75
Current: 3.04
1.18
5.75
Days Inventory 106.59
QGEN's Days Inventory is ranked lower than
55% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. QGEN: 106.59 )
Ranked among companies with meaningful Days Inventory only.
QGEN' s Days Inventory Range Over the Past 10 Years
Min: 94.1  Med: 119.51 Max: 160.09
Current: 106.59
94.1
160.09
Days Sales Outstanding 79.06
QGEN's Days Sales Outstanding is ranked lower than
61% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. QGEN: 79.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
QGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.21  Med: 71.01 Max: 76.79
Current: 79.06
58.21
76.79
Days Payable 42.56
QGEN's Days Payable is ranked lower than
62% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. QGEN: 42.56 )
Ranked among companies with meaningful Days Payable only.
QGEN' s Days Payable Range Over the Past 10 Years
Min: 35.09  Med: 47.07 Max: 68.16
Current: 42.56
35.09
68.16

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.58
QGEN's Price/Projected FCF is ranked higher than
68% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.92 vs. QGEN: 1.58 )
Ranked among companies with meaningful Price/Projected FCF only.
QGEN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.04  Med: 1.51 Max: 1.93
Current: 1.58
1.04
1.93
Price/Median PS Value 0.86
QGEN's Price/Median PS Value is ranked higher than
57% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. QGEN: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
QGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.73  Med: 1.00 Max: 1.29
Current: 0.86
0.73
1.29
Earnings Yield (Greenblatt) (%) 2.47
QGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. QGEN: 2.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 2.70 Max: 6
Current: 2.47
1.1
6
Forward Rate of Return (Yacktman) (%) 2.32
QGEN's Forward Rate of Return (Yacktman) (%) is ranked lower than
72% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. QGEN: 2.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
QGEN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.9  Med: 8.00 Max: 13.4
Current: 2.32
-1.9
13.4

More Statistics

Revenue(Mil) $1281
EPS $ 0.53
Beta0.81
Short Percentage of Float1.86%
52-Week Range $20.10 - 28.53
Shares Outstanding(Mil)233.01

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 1,343 1,408 1,449
EPS($) 1.11 1.17 1.29
EPS without NRI($) 1.11 1.17 1.29

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:QIA.Germany, QIA.Switzerland, 0H1Z.UK,
Qiagen NV provides Sample & Assay Technologies, based on market studies of United States and European market shares for its products and technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics. The Company markets more than 500 core products that are distributed in thousands of variations and combinations. In October 2012, the company announced a collaboration with Bayer HealthCare for development and commercialization of companion diagnostics paired with novel Bayer drugs, initially to enhance the treatment of various solid tumors. The Company has developed and advanced a broad range of technologies to extract and purify molecules of interest from biological samples such as blood, bone, tissue. It has also developed assays that enable the analysis of various kinds of molecules from virtually any biological sample. Assay technologies make information contained in isolated molecules visible and available for interpretation. The Company sells varied and flexible workflows for molecular testing, including sample and assay kits known as consumables and automated instrumentation platforms using those technologies, to four major customer classes: Molecular Diagnostics - healthcare providers supporting many aspects of patient care including prevention, profiling of diseases, personalized healthcare and point of need testing; Applied Testing - government or industry customers using molecular technologies in fields such as forensics, veterinary diagnostics and food safety testing; Pharma - drug discovery, translational medicine and clinical development efforts of pharmaceutical and biotechnology companies; Academia - researchers exploring the secrets of life such as the mechanisms and pathways of diseases. The Company markets its products in more than 100 countries throughout the world. The Company's competitors includes Promega Corp., EMD Millipore or Merck Millipore, and Macherey-Nagel GmbH for nucleic acid separation and purification; Thermo Fisher and Promega Corp. for assay solutions and for transfection reagents; and Sigma-Aldrich Corp. and Thermo Fisher for protein fractionation products. The Company is subject to a variety of laws and regulations in the European Union, the United States and other countries.
» More Articles for QGEN

Headlines

Articles On GuruFocus.com
David Herro's Oakmark International Small Cap Fund 4th Quarter Commentary Jan 08 2016 
Biotech Gets Personal: Long on Qiagen (QGEN) & SPDR S&P Biotech (XBI) Feb 29 2012 
Guru Stocks at 52-Week Lows: LMT, VIP, VMC, IRM, QGEN Oct 10 2010 
Weekly Guru Bargains Highlights: QGEN, BXS, ATHR, LYV, TFSL Oct 09 2010 

More From Other Websites
QIAGEN Launches Targeted RNA Panels for Next-generation Sequencing Feb 11 2016
QIAGEN and 10x Genomics to Enter Into Co-marketing and Co-development Collaboration Feb 09 2016
Edited Transcript of QGEN earnings conference call or presentation 3-Feb-16 2:30pm GMT Feb 03 2016
Qiagen Q4 Earnings Miss, Molecular Diagnostics Disappoints Feb 03 2016
New Agreements Underscore QIAGEN's Leadership in Bioinformatics Feb 02 2016
QIAGEN Reports Results for Fourth Quarter and Full-Year 2015 Feb 02 2016
Moving Average Crossover Alert: Qiagen (QGEN) Feb 02 2016
Q4 2015 Qiagen NV Earnings Release - 4:00 pm ET Feb 02 2016
QIAGEN to supply QuantiFERON-TB tests to ease tuberculin shortage Jan 26 2016
QIAGEN to Supply QuantiFERON-TB Tests to Ease Tuberculin Shortage Jan 26 2016
QIAGEN N.V. to Report Fourth Quarter and Full-year 2015 Results Jan 19 2016
Qiagen Q4 and 2015 Preliminary Results Dim; Shares Tank 13% Jan 13 2016
Qiagen Slumps: QGEN Falls 9.5% in Session Jan 12 2016
QIAGEN reaches milestone with portfolio of master collaboration agreements for pharma companion... Jan 11 2016
QIAGEN Reaches Milestone With Portfolio of Master Collaboration Agreements for Pharma Companion... Jan 11 2016
What is Going On With These 4 Plunging Stocks? Jan 11 2016
Why Shares Of Qiagen Plunged Early Monday Morning Jan 11 2016
Ad-hoc Announcement according to § 15 WpHG Jan 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK